Inventiva S.A. (IVA) Earnings Call Transcripts

Inventiva S.A.'s Latest Earnings Call - March 31, 2026

In the full year 2025 earnings call, Inventiva S.A. (IVA:FR) reported a strong financial position with EUR 230.9 million in cash, bolstered by significant financing events. The company is focused on its pivotal Phase III clinical trial, NATiV3, for lanifibranor, with top-line results expected in Q4 2026. Management emphasized the potential of lanifibranor in treating MASH, particularly its ability to improve fibrosis, which could position it as a leading therapy in this underdiagnosed market.

Reported metrics

Guidance from management

Management confirmed that the cash runway extends into mid-Q1 2027, supporting operations through the anticipated NATiV3 readout. They also indicated that they are prepared to meet FDA requirements for trial progress by the time of filing.

What management said

Dominic. So 2 questions. Let me take the second one first, and the first one over to Jason. Just on safety monitoring, there are periodic monitoring committee meetings every 6 months. you would know if they had said anything. Other than that, we really can't say anything about those meetings. Go ahead, Jason, on the biopsy.

[indiscernible] question, Mike. You were a little soft, so I'm just going to repeat some of it. So there was a question about does weight gain in these plateau and number one, from the Phase II. Number two, does that [indiscernible] there a chance of that weight gain would actually go down in the Phase III either due to concomitant medications or longer treatment -- and number three, some of the weight gain -- if the...

What analysts pressed on

Analysts expressed concerns regarding the dropout rates in the NATiV3 trial and the potential impact of background medications on treatment efficacy. There were also inquiries about the competitive landscape and how lanifibranor will differentiate itself in the market.

Main topics on the call

• NATiV3 Trial Update — Enrollment for the NATiV3 trial was completed in April 2025, and the top-line readout is now expected in Q4 2026. CEO Andrew Obenshain stated, "We believe the data from the NATiV3 trial, if positive, has the potential to...
• Financial Position — Inventiva reported EUR 230.9 million in cash and equivalents, providing a runway into Q1 2027. CFO Jean Volatier noted, "We estimate that we are funded beyond our anticipated NATiV3 readout."
• Market Potential for MASH — The company highlighted the growing awareness and diagnosis of MASH, with an estimated 18 million people in the U.S. living with the condition. Obenshain mentioned, "More patients are being identified, more being diagnos...
• Leadership Changes — Inventiva has strengthened its leadership team with new appointments in key roles, including Dr. Jason Campagna as CMO. This restructuring aims to enhance the company's focus on lanifibranor and its commercialization str...

Read the full Inventiva S.A. transcript (March 31, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 24 Inventiva S.A. earnings call transcripts on record, spanning March 10, 2020 to March 31, 2026. Based on this history, Inventiva S.A. reports quarterly. The most recent call on file is dated March 31, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IVA

Exchange

ENXTPA

Country

FR

Sector

Health Care

Industry

Biotechnology

Calls on record

24

First call

March 10, 2020

Most recent

March 31, 2026

Reporting cadence

quarterly